0001808665false00018086652024-11-072024-11-07

美国
证券交易委员会
华盛顿特区20549
 
表格 8-K
 
目前的报告
根据1934年证券交易法案第13或第15(d)节
 
报告日期(最早报告事项日期):2024年11月07日
 
assertio控股公司,INC。
(根据其章程规定的注册人准确名称)
 
特拉华州 01-39294 85-0598378
(注册或组织的)提起诉讼的州或其他司法管辖区(如适用)
1501 Yamato Road
 (设立或其它管辖地的州) (内部税务服务雇主识别号码)
 
100 S. Saunders Road, Suite 300, 莱克福里斯特伊利诺伊州 60045
(总部地址; 邮政编码)
 
(224) 419-7106
(注册人电话号码,包括区号)
 
 
(如果自上次报告以来地址或名称有所更改的前名称或前地址)

每个交易所的名称
每类股票名称:    交易标的名称:注册交易所的名称:
普通股,每股面值0.0001美元 ASRT纳斯达克股票交易所有限责任公司
 
如果在下列文件之下勾选适当的方框,表8-K的提交同时也是公司根据以下任一条规定的提交要求:根据A.2.中的一般说明:
 
                                   根据证券法规定的书面通信(17 CFR 230.425)
 
                                   根据交易法规定的征求意见材料(17 CFR 240.14a-12)
 
                                   根据交易法规定的事前沟通(17 CFR 240.14d-2(b))
 
                                   根据交易法规定的事前沟通(17 CFR 240.13e-4(c))
 
请打勾选择:注册人是否符合1933年证券法(本章节第230.405节)或者1934年证券交易法(本章节第2401.2亿.2节)中规定的新兴成长型企业。
 
新兴成长公司
 
如果一个新兴成长型公司,如果注册人选择不使用根据《证券交易法》第13(a)条规定提供的适用于遵守任何新的或修订后的财务会计准则的延长过渡期,请用复选标记表示。



项目2.02运营结果和财务状况。
2024年11月11日,assertio控股公司发布新闻稿,并举行电话会议讨论截至2024年9月30日三个月和九个月的财务结果。附件中分别附有新闻稿和电话会议记录作为展示99.1和99.2,并在此引用。
本目前报告表格8-k("表格8-K")第2.02项中的信息不应被视为根据经修订的1934年证券交易法第18条的目的而“已提交”。无论是在此之前还是之后,本文中包含的信息都不会被纳入公司提交给证券交易委员会(“SEC”)的任何备案文件中,无论该备案文件中是否有任何一般纳入条款。
事项5.02 董事离职或某些高管的任免;董事会成员的选举;某些高管的补偿安排。
彼得·斯泰普尔和杰弗里·瓦西卡退出董事会
2024年11月7日,彼得·斯泰普尔通知公司董事会(“董事会”)他打算于2024年11月7日(“生效日期”)生效辞去董事会成员的职务。斯泰普尔先生的养老并非因与公司在公司运营、政策或实践相关的任何事项产生争议或不一致。
2024年11月7日,Jeffrey Vacirca还通知公司董事会,他打算于生效日期生效之日起退休,不再担任董事会及其委员会成员。Vacirca博士的退休不是由于与公司在任何与公司运营、政策或实践有关的事项上发生争执或分歧。
任命David Stark为董事会成员
2024年11月7日,董事会任命David Stark加入董事会,任命日期起生效。与其加入董事会相关,Stark先生被任命为董事会提名和公司治理委员会委员。
斯塔克先生,56岁,曾担任梯瓦制药公司(“梯瓦制药”)的首席法律官,任期从2016年至2024年。斯塔克先生于2002年加入梯瓦制药,并在梯瓦北美和美洲的一系列职务中任职,包括担任高级董事、副总法律顾问、副总裁兼总法律顾问及全球专科药品高级副总裁兼总法律顾问。加入梯瓦之前,斯塔克先生在Willkie Farr & Gallagher LLP的诉讼部门任律师(1998年至2002年)、Chadbourne & Parke(1997年至1998年)和Haight, Gardner, Poor & Havens(1994年至1997年)任职。斯塔克先生是Stark Creative Solutions LLC的创始人兼首席执行官,专门提供创新解决法律挑战的方案。董事会考虑到斯塔克先生在以下与公司及其业务相关领域的经验和专长,得出他应该加入董事会的结论:法律经验、并购、公司管理和公司策略。斯塔克先生拥有纽约大学法学院法学硕士学位和东北大学政治学文学学士学位(优等生)。
关于他在董事会任职的事宜,斯塔克先生有权获得公司所有非雇员董事应得的薪酬和股权奖励,具体规定详见公司提交给证券交易委员会的2024年8月7日提交的10-Q表格附表10.4中的《公司非雇员董事薪酬和授予政策》。公司还与斯塔克先生签订了其标准形式的赔偿协议。
前瞻性声明
包含在本8-k表格中并通过引用纳入的声明包括前瞻性声明。前瞻性声明可能讨论未来计划、趋势、事件、运营结果或财务状况等方面的目标、意图和期望,或基于当前信念的其他内容。前瞻性声明仅在发布之日或声明中指示的日期作出,并不应被视为对未来事件的预测,因为无法保证这些声明反映的事件或情况将被实现或发生。前瞻性声明通常可以通过使用前瞻性术语来识别,包括“预期”,“近似”,“相信”,“可能”,“设计”,“估计”,“期望”,“目标”,“打算”,“可能”,“机会”,“展望”,“计划”,“潜在”,“项目”,“预期”,“审慎”,“寻求”,“应当”,“策略”,“目标”,“将”或这些词语的否定形式和短语,这些词语和短语的其他变体或类似术语。



These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the statements, including: the Company’s ability to grow sales of, and the commercial success and market acceptance of, Rolvedon and the Company’s other products; the Company’s ability to successfully develop and execute its sales, marketing and promotion strategies using its sales force and non-personal promotion model capabilities; the impact on sales and profits from the entry and sales of generics of the Company’s products and/or other products competitive with any of the Company’s products (including indomethacin suppositories compounded by hospitals and other institutions including a 503B compounder which the Company believes to be violation of certain provisions of the Food, Drug and Cosmetic Act); the timing and impact of additional generic approvals and uncertainty around the recent approvals and launches of generic Indocin products (which are not patent protected and now face generic competition as a result of the August 2023 approval and launch of generic indomethacin suppositories and January 2024 approval and subsequent launch of a generic indomethacin oral suspension product); risks that any new businesses will not be integrated successfully or that the combined company will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer and/or cost more to realize than expected; expected industry trends, including pricing pressures and managed healthcare practices; the Company’s ability to attract and retain executive leadership and key employees; the ability of the Company’s third-party manufacturers to manufacture adequate quantities of commercially salable inventory and active pharmaceutical ingredients for each of the Company’s products on commercially reasonable terms and in compliance with their contractual obligations to the Company, and the Company’s ability to maintain its supply chain which relies on single-source suppliers; the outcome of, and the Company’s intentions with respect to, any litigation or government investigations, including pending and potential future shareholder litigation relating to the Spectrum Merger and/or the recent approval and launch of generic indomethacin suppositories, opioid-related government investigations and opioid-related litigation, the recently unsealed qui tam litigation, as well as Spectrum’s legacy shareholder and other litigation, and other disputes and litigation, and the costs and expenses associated therewith; the Company’s financial cost and outcomes of clinical trials, including the extent to which data from the Rolvedon same-day dosing trial may support ongoing commercialization efforts; the Company’s compliance with legal and regulatory requirements related to the development or promotion of its products; variations in revenues obtained from commercialization agreements and the accounting treatment with respect thereto; the Company’s common stock maintaining compliance with The Nasdaq Capital Market’s minimum closing bid requirement of at least $1.00 per share, particularly in light of our stock trading below or only slightly above $1.00 per share recently as well as recent market activity by a short seller; and the Company’s ability to obtain and maintain intellectual property protection for its products and operate its business without infringing the intellectual property rights of others. For a discussion of additional factors that could cause actual results to differ materially from those contemplated by forward-looking statements, see the risks described in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC. Many of these risks and uncertainties may be exacerbated by public health emergencies and general macroeconomic conditions. The Company does not assume, and hereby disclaims, any obligation to update forward-looking statements, except as may be required by law.
Non-GAAP Financial Measures
To supplement the Company’s financial results presented on a U.S. generally accepted accounting principles (“GAAP”) basis, the Company has included and/or incorporated by reference into this Form 8-K information about non-GAAP measures of EBITDA, adjusted EBITDA, adjusted earnings, adjusted earnings per share, and adjusted operating expenses as useful operating metrics. The Company believes that the presentation of these non-GAAP financial measures, when viewed with results under GAAP provides supplementary information to analysts, investors, lenders, and the Company’s management in assessing the Company’s performance and results from period to period. The Company uses these non-GAAP measures internally to understand, manage and evaluate the Company’s performance and, in part, in the determination of bonuses for executive officers and employees. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income or other financial measures calculated in accordance with GAAP. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.
The statements included in and/or incorporated by reference into this Form 8-K also include estimated full-year non-GAAP adjusted EBITDA and estimated full-year non-GAAP operating expense information, which the Company believes enables investors to better understand the anticipated performance of the business, but should be considered a supplement to, and not as a substitute for or superior to, financial measures calculated in accordance with GAAP. No reconciliations of these non-GAAP metrics are provided because some of the information necessary to estimate the most directly comparable financial measures calculated in accordance with GAAP, such as income taxes, fair value change in contingent consideration, and stock-based compensation, is not yet ascertainable or accessible and the Company is unable to quantify these amounts that would be required to be included in such estimates without unreasonable efforts.



Specified Items
Non-GAAP measures included in and/or incorporated by reference into this Form 8-K exclude specified items. The Company considers specified items to be significant income/expense items not indicative of current operations. Specified items may include adjustments to interest expense and interest income, income tax expense (benefit), depreciation expense, amortization expense, sales reserves adjustments for products the Company is no longer selling, stock-based compensation expense, fair value adjustments to contingent consideration or derivative liability, restructuring charges, amortization of fair value inventory step-up as a result of purchase accounting, transaction-related costs, gains, losses or impairments from adjustments to long-lived assets and assets not part of current operations, changes in valuation allowances on deferred tax assets, and gains or losses resulting from debt refinancing or extinguishment.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits
99.1
99.2
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
 



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 ASSERTIO HOLDINGS, INC.
   
Date: November 12, 2024
By:/s/ Brendan P. O’Grady
  Brendan P. O’Grady
  Chief Executive Officer
(Principal Executive Officer)